Kazia Therapeutics Ltd
KZIA10.870USD
+0.890+8.92%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
87.98MMarket Cap
LossP/E TTM
More Details of Kazia Therapeutics Ltd Company
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd Info
Ticker SymbolKZIA
Company nameKazia Therapeutics Ltd
IPO dateSep 01, 1994
CEOFriend (John E)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endSep 01
AddressThree International Towers Level 24,
CitySYDNEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code2000
Phone1161298780088
Websitehttps://www.kaziatherapeutics.com/
Ticker SymbolKZIA
IPO dateSep 01, 1994
CEOFriend (John E)
Company Executives of Kazia Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
1.98K
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
1.71K
--
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chernett (Jorey)
1.28%
Dauntless Investment Group, LLC
1.10%
Alumni Capital Management LLC
0.26%
Barclays Capital Inc.
0.22%
Rockefeller Capital Management
0.10%
Other
97.03%
Shareholders
Shareholders
Proportion
Chernett (Jorey)
1.28%
Dauntless Investment Group, LLC
1.10%
Alumni Capital Management LLC
0.26%
Barclays Capital Inc.
0.22%
Rockefeller Capital Management
0.10%
Other
97.03%
Shareholder Types
Shareholders
Proportion
Individual Investor
1.39%
Investment Advisor
1.24%
Investment Advisor/Hedge Fund
0.27%
Research Firm
0.23%
Other
96.88%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
38
172.48K
10.65%
+130.03K
2025Q2
38
284.07K
17.55%
+238.97K
2025Q1
39
31.11K
2.29%
-13.78K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
2023Q2
34
28.95K
1.27%
-34.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chernett (Jorey)
137.20K
8.48%
+137.20K
--
Jun 11, 2025
Dauntless Investment Group, LLC
115.77K
7.15%
+115.77K
--
Jun 30, 2025
Alumni Capital Management LLC
28.41K
1.75%
+28.41K
--
Sep 12, 2025
Barclays Capital Inc.
24.00K
1.48%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
2.83K
0.18%
-2.42K
-46.07%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 01, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Date
Type
Ratio
Apr 01, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Mar 06, 2025
Merger
5→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
Oct 15, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Kazia Therapeutics Ltd?
The top five shareholders of Kazia Therapeutics Ltd are:
Chernett (Jorey) holds 137.20K shares, accounting for 8.48% of the total shares.
Dauntless Investment Group, LLC holds 115.77K shares, accounting for 7.15% of the total shares.
Alumni Capital Management LLC holds 28.41K shares, accounting for 1.75% of the total shares.
Barclays Capital Inc. holds 24.00K shares, accounting for 1.48% of the total shares.
UBS Financial Services, Inc. holds 2.83K shares, accounting for 0.18% of the total shares.
Chernett (Jorey) holds 137.20K shares, accounting for 8.48% of the total shares.
Dauntless Investment Group, LLC holds 115.77K shares, accounting for 7.15% of the total shares.
Alumni Capital Management LLC holds 28.41K shares, accounting for 1.75% of the total shares.
Barclays Capital Inc. holds 24.00K shares, accounting for 1.48% of the total shares.
UBS Financial Services, Inc. holds 2.83K shares, accounting for 0.18% of the total shares.
What are the top three shareholder types of Kazia Therapeutics Ltd?
The top three shareholder types of Kazia Therapeutics Ltd are:
Chernett (Jorey)
Dauntless Investment Group, LLC
Alumni Capital Management LLC
Chernett (Jorey)
Dauntless Investment Group, LLC
Alumni Capital Management LLC
How many institutions hold shares of Kazia Therapeutics Ltd (KZIA)?
As of 2025Q3, 38 institutions hold shares of Kazia Therapeutics Ltd, with a combined market value of approximately 172.48K, accounting for 10.65% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -6.89%.
What is the biggest source of revenue for Kazia Therapeutics Ltd?
In FY2022, the -- business generated the highest revenue for Kazia Therapeutics Ltd, amounting to -- and accounting for --% of total revenue.
